Successful systemic low-dose lysis of a caval thrombus by rt-pa in a neonate with congenital nephrotic syndrome

American Journal of Pediatric Hematology/Oncology

Volumn 19, Issue 4, 1997, Pages 348-350

  Kändler, Christoph ^a   Ries, Martin ^a   Rupprecht, Thomas ^a   Ruder, Hans ^a   Harms, Dieter ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Caval thrombosis; Congenital nephrotic syndrome; Key Words; Low dose rt PA; Newborn

Indexed keywords

ALTEPLASE; ANTITHROMBIN III; HEPARIN;

ARTICLE; CASE REPORT; CAVA VEIN DISEASE; CONGENITAL NEPHROTIC SYNDROME; FIBRINOLYTIC THERAPY; HUMAN; MALE; NEWBORN; PRIORITY JOURNAL; TREATMENT OUTCOME; VEIN THROMBOSIS;

DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT, NEWBORN; NEPHROTIC SYNDROME; PREGNANCY; RECOMBINANT PROTEINS; RENAL VEINS; THROMBOPHLEBITIS; TISSUE PLASMINOGEN ACTIVATOR; VENA CAVA, INFERIOR;

EID: 0342601890     PISSN: 01928562     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-199707000-00015     Document Type: Article

References (13)

1. Anderson BJ, Keeley SR, Johnson D. Caval thrombolysis in neonates using low doses of recombinant human issue-type plasminogen activator. Anaesth Intensive Care 1991;19:22-7.
2. Mehls O, Andrassy K, Koderisch J, et al. Hemostasis and thromboembolism in children with nephrotic syndrome: Differences from adults. J Pediatr 1987;110:862-7.
3. Kreuz W, Heller C, Lenz E. Thrombolyse mit rt-PA im Kindesaltereine Übersicht. Fibrinolyse 1996;1:2:4-10.
4. Andrew M, Paes B, Milner R, et al. Development of human coagulation system in the full-term infant. Blood 1987;70:165-72.
5. Holmberg C, Laine J, Rönnholm K, et al. Congenital nephrotic syndrome. Kidney Int 1996;49, Suppl. 53:S51-6.
6. Andrew M, Brooker LA. Hemostatic complications in renal disorders of the young. Pediatr Nephrol 1996;10:88-99.
7. Schmidt B, Mitchell L, Ofosu F, et al. Standard assays underestimate the concentration of heparin in neonatal plasma. J Lab Clin Med 1988;112:641-3.
8. Vieira A, Ofosu F, Andrew M. Heparin sensitivity and resistance in the neonate: an explanation. Thromb Res 1991;25:405-8.
9. Nowak-Göttl U, Kreutz D, Schwabe D, et al. Thrombolyse mit rt-PA bei Kindern mit arteriellen und venösen Thrombosen-ein neuer therapieansatz. Klin Pädiatr 1991;203:359-62.
10. Nowak-Göttl U, Schwabe D, Schneider W, et al. Thrombolysis with recombinant tissue-type plasminogen activator in renal venous thrombosis in infancy. Lancet 1992;340:1105 (letter).
11. Ries M, Klinge J, Rauch R, et al. in vitro fibrinolysis after adding low doses of plasminogen activators and Plasmin generation with and without oxidative inactivation of Plasmin inhibitors in newborn and adults. J Pediatr Hematol Oncol 1996;18:346-51.
12. Ries M, Zenker M, Klinge J, et al. Age-related differences in a clot lysis assay after adding different plasminogen activators in a plasma milieu in vitro. J Pediatr Hematol Oncol 1995;17:260-4.
13. Levy M, Benson LN, Burrows PE, et al. Tissue plasminogen activator for the treatment of thromboembolism in infants and children. J Pediatr 1991;118:467-72.